These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Prevalence of drug resistance in Dharmapuri and A. Pallipatti areas of Tamil Nadu. Sreevatsa ; Ramu G; Desikan KV Indian J Lepr; 1985; 57(2):376-82. PubMed ID: 3908580 [TBL] [Abstract][Full Text] [Related]
43. Characteristics of the multiplication of dapsone-resistant strains of Mycobacterium leprae in mice. Subcommittee on Clinical Trials of the C hemotherapy of Leprosy (THELEP) Scientific Working Group of UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Lepr Rev; 1988 Mar; 59(1):5-10. PubMed ID: 3294541 [No Abstract] [Full Text] [Related]
45. Observations on the cultivation of M. leprae and M. tuberculosis in medium 'V' and 'V 1'. Herbert D; Prabhakar R Indian J Lepr; 1992; 64(3):341-7. PubMed ID: 1431323 [TBL] [Abstract][Full Text] [Related]
46. Controlled long-term therapy of leprosy with B663 (lamprene, clofazimine) compared with DDS. Tolentino JG; Rodriquez JN; Abalos RM Int J Lepr Other Mycobact Dis; 1974; 42(4):416-418. PubMed ID: 4617720 [No Abstract] [Full Text] [Related]
47. A quantitative basis for sustainable anti-Mycobacterium leprae chemotherapy in leprosy control programs. Almeida JG Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):255-68. PubMed ID: 1522367 [No Abstract] [Full Text] [Related]
48. The problem of dapsone-resistant leprosy. Pearson JM Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):417-20. PubMed ID: 7042605 [No Abstract] [Full Text] [Related]
49. Dapsone resistance in leprosy. Browne SG Trans St Johns Hosp Dermatol Soc; 1973; 59(2):225-9. PubMed ID: 4602407 [No Abstract] [Full Text] [Related]
50. Prevalence of secondary dapsone resistance in Nepal. Samuel NM; Samuel S; Loudon J; Neupani K; Adiga RB Indian J Lepr; 1984; 56(4):823-7. PubMed ID: 6398344 [TBL] [Abstract][Full Text] [Related]
52. Dormancy, drug resistance or dependency; some thoughts to ponder. Shetty VP; Mistry NF; Uplekar MW; Antia NH; Pai VV; Ganapati R Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):455-7. PubMed ID: 9030116 [No Abstract] [Full Text] [Related]
53. The activity of a thiadiazole on Mycobacterium leprae. Levy L Proc Soc Exp Biol Med; 1976 Oct; 153(1):34-6. PubMed ID: 792890 [No Abstract] [Full Text] [Related]
54. Activity of thiozamin (p-(p'-aminobenzenesulfonyl)-benzaldehyde thiosemicarbazone) against Mycobacterium leprae infections in mice. Matsuo Y Jpn J Microbiol; 1971 Jan; 15(1):93-4. PubMed ID: 4927841 [No Abstract] [Full Text] [Related]
55. [Streptomycin therapy of leprosy]. ORRU A Rass Med Sarda; 1952; 54(3-4):106-14. PubMed ID: 14949486 [No Abstract] [Full Text] [Related]
56. Means of increasing the tolerated dose of streptomycin in mice. PRESCOTT B; KAUFFMANN G; JAMES WD Antibiot Chemother (Northfield); 1958 Jan; 8(1):27-32. PubMed ID: 24544649 [No Abstract] [Full Text] [Related]
57. Failure of streptomycin in the treatment of leprosy. CUTTLE TD Am J Med Sci; 1947 Oct; 214(4):385-8. PubMed ID: 20266935 [No Abstract] [Full Text] [Related]
58. [Streptomycin in the treatment of leprosy]. TZANCK ; BASSET Bull Soc Fr Dermatol Syphiligr; 1950; 57(2):207-9. PubMed ID: 15434639 [No Abstract] [Full Text] [Related]
59. Streptomycin in leprosy, early cutaneous type. GARDUNO DM; DE LEON DM J Philipp Med Assoc; 1951 Feb; 27(2):93-101. PubMed ID: 14825108 [No Abstract] [Full Text] [Related]
60. Evaluation of the activity of streptomycin on Mycobacterium leprae in mice. Pattyn SR; Saerens E Lepr Rev; 1978 Dec; 49(4):275-81. PubMed ID: 368476 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]